Acute myocardial infarction is triggered by coronary artery occlusion that may be recanalized by thrombolytic therapy with a success rate of up to 75% only. The resistance of coronary artery occlusion to thrombolysis may either be due to obstruction of the lumen by a nonthrombotic mechanism or by intrinsic resistance of thrombus to dissolution. Coronary arterial thrombi are composed of platelet-rich and erythrocyte-rich material in variable proportions. To evaluate the relative sensitivity of these thrombus components to thrombolysis, we have used two femoral arterial thrombosis models in the rabbit, consisting of erythrocyterich clot produced by injecting whole blood and thrombin in an isolated segment and of platelet-rich thrombus spontaneously formed on an everted (inside out) femoral arterial segment. Intravenous infusion of recombinant tissue-type plasminogen activator (rt-PA) at a rate of 30 ,ug/kg/min consistently reperfused arteries occluded with erythrocyte-rich clot (six of six animals compared with zero of six placebo-treated animals, p=0.002), whereas infusion of 30 or 100 ,g/kg/min was significantly less efficient for reperfusion of everted segments occluded with platelet-rich material (only four of 12 animals, p=0.01). Intra-arterial infusion proximal to the occlusion, at a rate of 20 ,ug/kg/min reperfused six of seven rabbits with erythrocyte-rich clots but only one of seven rabbits with occluded everted segments (p=0.03). A dose of 100 ,ug/ kg/min was necessary to reperfuse platelet-rich occlusions in five of six rabbits. We conclude that platelet-rich arterial thrombus is much more resistant to thrombolysis with rt-PA than erythrocyte-rich clot. This differential sensitivity to lysis may explain the failure of thrombolytic therapy in a significant percentage of patients with acute myocardial infarction who may have a predominantly platelet-rich occlusion. The rabbit femoral arterial eversion graft model may represent a useful tool for developing strategies directed at the dissolution of platelet-rich thrombus. (Circulation 1989;79:920-928) Presented in part at the 61st Scientific Meetings of the American Heart Association, Washington, DC, November 14-17, 1988. Supported in part by ISCHEMIA SCOR Grant (HL-25215) and THROMBOSIS SCOR Grant 
occlusions may be due to luminal compression by intraplaque hemorrhage or coronary arterial dissection or to intrinsic resistance of the clot to lysis, which occurs as a result of variable clot architecture or composition.
Postmortem microscopic examination of serial sections of coronary thrombus of patients with acute myocardial infarction and sudden death has revealed that thrombus formed at the plaque fissure is very rich in platelets, whereas proximal and distal extensions of the thrombus are composed of erythrocyte-rich material.8 Thus, both platelet-rich and erythrocyte-rich zones are present in coronary thrombus, occasionally in several layers,9 and their relative contribution to thrombus mass and to occlusion of the cross-sectional luminal area may vary.
Preformed whole blood or plasma clots immersed in citrated plasma in vitro are readily lyzed with tissue-type plasminogen activator (t-PA) at concentrations of a few micrograms per milliliter,10 whereas platelet aggregates induced in platelet-rich plasma require at least a tenfold higher concentration of rt-PA for disaggregation.1" This indicated to us that platelet-rich regions of coronary clot may be more resistant to lysis than erythrocyte-rich regions and that resistance of coronary thrombus to lysis may, at least in part, be due to a relative preponderance of platelet-rich material.
Therefore, we investigated the efficacy of rt-PA for arterial reperfusion in two arterial thrombosis models in the rabbit, one consisting of occlusive whole blood clot and the other primarily composed of platelet-rich material.
Methods
Reagents rt-PA (Activase) was supplied by Genentech, South San Francisco, California.
Femoral Artery Eversion Graft Model (Platelet-Rich Thrombus Model) Initially, the model developed by Hergrueter et al12 was used with minor modifications as described below. New Zealand White rabbits weighing from 2.2 to 3.4 kg were anesthetized by intramuscular injection of 2/3 ml ketamine (Ketalar, 100 mg/ml, Parke-Davis, Morris Plains, New Jersey) and 1/3 ml xylazine (Rompun, 100 mg/ml, Mobay, Shawnee, Kansas). A sutures with 10-0 nylon (Sharpoint, Reading, Pennsylvania). The microvascular clamp that clamped off the proximal and distal ends of the transsected artery was released, the vessel was observed for 10 minutes, and the patency assessed by distal milking at 5-minute intervals as follows. The femoral artery was occluded distally to the eversion graft by external compression with blunt forceps. A segment of approximately 1 cm was emptied of blood by compression with a second forceps that was moved distally. Then, the proximal forceps was released to observe whether or not the empty segment was filling with blood through the everted arterial segment. The contralateral femoral vein was cannulated for baseline blood sampling and for intravenous infusion of rt-PA or placebo with a constant rate infusion pump (Syringe infusion pump 22, Harvard Apparatus, South Natick, Massachusetts).
After an initial series of experiments in 14 rabbits, the model was improved in the following ways ( Figure 1 ). Anesthesia was performed with intravenous injection of sodium pentobarbital (35 mg/kg followed by 10 mg at 30-60-minute intervals) through a marginal ear vein or femoral vein. The right brachial artery was cannulated with Intracath 23 gauge (Deseret Medical, Becton Dickinson, Sandy, Vermont) for blood pressure monitoring and blood sampling 50 minutes after the start of the infusion. Blood flow in the left femoral artery containing the everted graft was continuously monitored with an ultrasonic flowmeter (T101 Ultrasonic blood flowmeter, Transsonic Systems, Ithaca, New York). When the flow had decreased to less than 0.5 ml/ min, the vessel was considered occluded, and heparin was given through the cannulated femoral vein (bolus of 200 units/kg followed by 70 units/kg at hourly intervals 
Evaluation of Platelet Aggregation
Six rabbits were anesthetized with sodium pentobarbital and 10 ml blood was collected through the femoral vein into plastic tubes containing 100 gl of 40% trisodium citrate for platelet aggregation studies. rt-PA was then infused at a rate of 20 jg/kg/min for 30 minutes through the cannulated femoral vein. After 25-30 minutes of the infusion, blood was collected for platelet aggregation through the cannulated right brachial artery. At the end of the first infusion, the infusion rate was increased to 80 ,ug/ kg/min for 30 minutes, and blood was again collected toward the end of the second infusion.
Platelet-rich plasma was obtained by centrifugation at 800g for ,g/kg/min and at 100 ,ug/kg/min produced lower systemic rt-PA levels and less extensive systemic fibrinogen breakdown than the comparable intravenous infusions. This is probably due to a significant loss of rt-PA by slow leakage through the proximal anastomosis during the arterial infusion. However, systemic rt-PA levels produced by intra-arterial infusion of rt-PA at 100 ,gg/kg/min were comparable to those obtained with intravenous infusion of rt-PA at 30 ,ug/kg/min. Partial thromboplastin times were in excess of 100 seconds in all animals. Table 3 shows some more detailed results obtained in the arterial eversion graft model. Baseline flow in the femoral artery averaged [11] [12] [13] [14] [15] [16] ml/min. The length of the everted segment was between 5.1 and 6.4 mm as determined by micrometry under the surgical microscope. This segment length was significantly shorter than the 10.5 to 10.7 mm segment isolated for production of the whole blood clot. The time to occlusion ranged between groups from 6 to 12 minutes. Reperfusion, when observed, restored blood flow to approximately 50% of the baseline value. Table 4 shows results of ADP-induced platelet aggregation and the effects of infusion or in vitro addition of rt-PA on platelet disaggregation. When platelet aggregation was induced with 18 /LM ADP, extensive rapid aggregation was observed with no change after in vivo infusion of rt-PA and a small but significant disaggregation after in vitro addition of 100 ,g/ml of rt-PA (p = 0.03 compared with baseline). With 2 ,M ADP, platelet aggregation was less extensive, but rapid and some spontaneous disaggregation was observed. In vivo rt-PA infusion did not influence the rate nor extent of platelet aggregation, but disaggregation was significantly augmented after in vitro addition of rt-PA to a final concentration of 100 ,ug/ml (p = 0.01). Figure 3 illustrates platelet aggregation curves obtained in one representative experiment. Pathologic Examination Figure 4 represents photomicrographs of femoral arterial segments of the whole blood clot (erythrocyterich) model before (Panel A) and after (Panel B) reperfusion. The whole blood clot is firmly anchored to the disrupted arterial wall and is morphologically very similar to the "head" region of coronary arterial thrombus.8 After reperfusion, the clot is reduced to some residual cells along the arterial wall. Figure  5 represents photomicrographs of the everted arterial graft (platelet-rich) model before (Panel A) and after (Panel B) reperfusion. The spontaneously formed thrombus is morphologically very similar to the "body" region of coronary arterial thrombus8 and is intimately attached to the adventitia. After reperfusion, residual platelet-rich clot is still evident. The morphologic characteristics of the arterial eversion model are further illustrated in Figure 6 , which represents a light photomicrograph of a section obtained after occlusion stained with PTAH showing adventitial collagen fiber anchored into the platelet-rich thrombus.
Discussion
The aim of the present study was to determine whether or not there is a difference in sensitivity between erythrocyte-rich and platelet-rich arterial thrombus to lysis with rt-PA. Such differential sensitivity would support the hypothesis that the relative erythrocyte and platelet content The present study, performed in rabbit models, shows that platelet-rich material occluding a femoral arterial eversion graft is indeed much more resistant to lysis with intravenous or intra-arterial rt-PA than erythrocyte-rich whole blood clots. Indeed, intravenous infusion of rt-PA at a rate of 30 ,g/kg/min, which results in plasma rt-PA levels of approximately 3 ,g/ml, readily dissolved whole blood clots, whereas an infusion rate of 100 ,g/kg/ min, which was associated with a plasma rt-PA level of 22±5 ,ug/ml and extensive systemic fibrinogen breakdown, did not dissolve the platelet-rich thrombus in the arterial eversion graft. However, our findings that platelet-rich occlusive material may be lyzed with local rt-PA infusion at a rate of 100 ,ug/kg/min indicates that the resistance to lysis is not absolute. These in vivo results confirm and extend the in vitro observation that whole blood clots are much more sensitive to lysis by rt-PA10 than platelet aggregates.11 The mechanism by which platelet-rich thrombus dissolves in vivo may be similar to that of in vitro platelets disaggregation as suggested by our findings that high local concentrations are required both to dissolve platelet-rich thrombus in vivo (infusion of 330 ,ul/min of rt-PA solution at a concentration of 0.75 mg/ml) and to disaggregate platelet clumps in vitro (100 Lg/ml plasma). However, these high local rt-PA concentrations in vivo do not result in systemic alteration of ADP-induced aggregation. Reocclusion of the arterial eversion graft after dissolution of the plateletrich thrombus did not occur during continued infusion of rt-PA but was usually observed within 15 minutes after the end of the 1-hour rt-PA infusion. This may relate to the short half-life of the rt-PA, which results in rapidly decreasing plasma levels and may indicate that the maintenance of vessel patency requires either continued rt-PA infusion over longer time periods or interference with the mechanism of platelet deposition.
In our study, the dosages of 100 ,ug/kg/min of intra-arterial rt-PA required to reperfuse occluded everted graft segments only 6 mm long, were apparently much higher than the 1-2 ,ug/kg/min used by Hergrueter et al'2 for the consistent reperfusion of everted grafts 1 cm long. Much of this difference, however, may be because we attempted to remove occlusive material formed in the absence of exogenous rt-PA infusion, whereas Hergrueter et al'2 reperfused grafts occluded after termination of a 4-hour infusion of rt-PA. It is indeed well known that clots formed in the presence of low doses of rt-PA are much more susceptible to lysis than preformed clots,16 and this phenomenon may also apply to the platelet-rich occlusive material. This hypothesis would also explain that intravenous infusion of rt-PA at a dose sufficient to maintain the circulating blood level of rt-PA above 0.35 ,ug/ml effectively prevents short-term reocclusion in patients with acute myocardial infarction.17
Most animal models for coronary thrombolysis have been developed with the use of whole blood clots in isolated segments of the coronary artery' In conjunction with the results of the present animal studies, these preliminary clinical observations in patients with acute myocardial infarction suggest that efforts to increase the efficacy of coronary thrombolysis to more than 75% should be directed toward the dissolution of platelet-rich thrombus. In this context, the rabbit femoral arterial eversion graft thrombosis model may constitute a useful tool for the investigation of such new thrombolytic agents and strategies. 
